Funding

Bacterial glycoprotein antigens for vaccine development

Funding

Investment

GlyProVac ApS is founded and owned by Anders Boysen backed by Science Ventures Denmark (SVD) and personal investments from co-founder Ann Zahle Andersen and co-inventors of the original BEMAP technology Jakob Møller-Jensen, Martin Røssel Larsen and Giuseppe Palmisano. GlyProVac ApS has received equity funding from Syddansk Innovation (SDI) and Styrelsen for Institutioner og Uddannelsesstøtte (SIU).


Current and previous soft funding

InnoBooster: GlyProVac ApS has been awarded a 400.000 DKK InnoBooster grant from the Danish Innovation Foundation in support of the nine months development project titled “Udvikling af bredspektret bakteriel vaccinekandidat – det vigtige valg af dyremodel”, The project runs from May 2020.


InnoBooster: GlyProVac ApS has been awarded a 1 million DKK InnoBooster grant from the Danish Innovation Foundation in support of the two-year development project titled “GlyProVac - Bacterial glycoprotein antigens for vaccine development”. The project was successfully concluded in March 2020.


Novo pre-seed grant: In 2014, during the early proof of principle phase at university of Southern Denmark, the GlyProVac project was supported with 2 million DKK from the Novo Pre-seed program. 


SDU proof of concept grant: In 2014 the internal PoC-board of University of Southern Denmark supported the early GlyProVac proof of concept project with 750.000 DKK.


Copyright © All Rights Reserved